ApaTech steps up US synthetic bone graft drive
This article was originally published in Clinica
UK synthetic bone graft developer ApaTech is stepping up for the next stage in its own development with the establishment of US operations. The London, UK-based spin-out of Queen Mary University recently obtained FDA 510(k) clearance for its Pore-Si and ApaPore products, and is aiming to "capture significant market share in the US", according to ApaTech Inc's new president, Steve Czick.
You may also be interested in...
With many non-CE marked products being allowed onto various EU member state markets, who is going to monitor compliance? TÜV-SÜD’s Bassil Akra calls for cooperation to avoid unsafe products being used on patients.
Indian drug makers appear confident of meeting both domestic and global requirements for hydroxychloroquine sulphate after India relaxed export curbs on the product, subject to strict monitoring, against the backdrop of requests from global heads of government for supplies of the potential treatment for COVID-19.
CEO breaks down to Scrip how the Hong Kong-based company managed its way through the coronavirus outbreak in China, saying improvisation was critical.